IL-1β inhibits self-renewal capacity of dormant CD34 +/CD38- acute myelogenous leukemia cells in vitro and in vivo

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1967-1981

  Yang, Jing ^a   Ikezoe, Takayuki ^a   Nishioka, Chie ^a   Nobumoto, Atsuya ^a   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

IL 1 ; leukemia stem cells; quiescence; STAT5

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTARABINE; IMATINIB; INTERLEUKIN 1BETA; JANUS KINASE 2; STAT5 PROTEIN; SUNITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CANCER TRANSPLANTATION; CD34+ CD38+ LEUKEMIA CELL; CD34+ CD38- LEUKEMIA CELL; CELL CYCLE PROGRESSION; CELL ISOLATION; CELL RENEWAL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG POTENTIATION; ENGRAFTMENT; ENZYME ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IL 1B GENE; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LEUKEMIA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION;

IL-1Β; LEUKEMIA STEM CELLS; QUIESCENCE; STAT5;

ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; DOWN-REGULATION; HUMANS; INTERLEUKIN-1BETA; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84881552121     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28198     Document Type: Article

References (42)

1. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
2. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005; 105: 3420-7.
3. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-59.
4. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18.
5. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
6. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-21.
7. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38antibody- mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-75.
8. Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc- deficient mice. J Clin Invest 2011; 121: 384-95.
9. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004; 5: 253-8.
10. Schuringa JJ, Wierenga AT, Kruijer W, et al. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765-70.
11. Ikezoe T, Yang J, Nishioka C, et al. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+)/CD38(-) cells and sensitizes them to antileukemia agents. Int J Cancer 2011; 128: 2317-25.
12. Ikezoe T, Kojima S, Furihata M, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer 2011; 129: 2512-21.
13. Pascale RL,. The Interleukin-1 family. Eur Cytokine Netw 1998; 9: 565-76.
14. Dinarello CA,. Biological basis for interleukin-1 in disease. Blood 1996; 87: 95-147.
15. Burger D, Molnarfi N, Gruaz L, et al. Differential induction of IL-1beta and TNF by CD40 ligand or cellular contact with stimulated T cells depends on the maturation stage of human monocytes. J Immunol 2004; 173: 1292-7.
16. Freedman AS, Freeman G, Whitman J, et al. Pre-exposure of human B cells to recombinant IL-1 enhances subsequent proliferation. J Immunol 1988; 141: 3398-404.
17. Vesey DA, Cheung C, Cuttle L, et al. Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor beta-dependent mechanism. J Lab Clin Med 2002; 140: 342-50.
18. Maier JA, Voulalas P, Roeder D, et al. Extension of the life-span of human endothelial cells by an interleukin-1 antisense oligomer. Science 1990; 249: 1570-4.
19. Komeva EA, Shanin SN, Rybakina EG,. The role of interleukin-1 in stress-induced changes in immune system function. Neurosci Behav Physiol 2001; 31: 431-7.
20. Onozaki K, Tamatani T, Hashimoto T, et al. Growth inhibition and augmentation of mouse myeloid leukemic cell line differentiation by Interleukin-1. Cancer Res 1987; 47: 2397-402.
21. Lachman LB, Dinarello CA, Llansa ND, et al. Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. J Immunol 1986; 136: 3098-102.
22. Nishioka C, Ikezoe T, Yang J, et al. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 2010; 24: 1631-40.
23. - acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Int J Cancer 2013; 132: 2006-19.
24. Ikezoe T, Tanosaki S, Krug U, et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004; 104: 237-42.
25. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-7.
26. Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5: 2522-30.
27. Hegde S, Hankey P, Paulson RF,. Self-renewal of leukemia stem cells in friend virus-induced erythroleukemia requires proviral insertional activation of Spi1 and Hedgehog signaling but not mutation of p53. Stem Cells 2012; 30: 121-30.
28. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005; 4: 578-86.
29. Hashimoto K, Oreffo RO, Gibson MB, et al. DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes. Arthritis Rheum 2009; 60: 3303-13.
30. Vockentanz L, Broske AM, Rosenbauer F,. Uncovering a unique role for DNA methylation in hematopoietic and leukemic stem cells. Cell Cycle 2010; 9: 640-1.
31. Trowbridge JJ, Sinha AU, Zhu N, et al. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012; 26: 344-9.
32. Cimmino L, Abdel-Wahab O, Levine RL, et al. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011; 9: 193-204.
33. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-18.
34. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-67.
35. Yong AS, Stephens N, Weber G, et al. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 2011; 25: 629-37.
36. Viré E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-4.
37. Campbell CJ, Lee JB, Levadoux-Martin M, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010; 116: 1433-42.
38. Xiang Z, Luo H, Payton JE, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest 2010; 120: 2109-18.
39. Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010; 7: 186-97.
40. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-88.
41. Radtke S, Wüller S, Yang XP, et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci 2010; 123: 947-59.
42. Turzanski J, Grundy M, Russell NH, et al. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia 2004; 18: 1662-70.